An April 2017 study published in Diabetes Technology & Therapeutics examined the risk of fasting during Ramadan for people with type 1 diabetes compared with a blood glucose control group and the rates of hypoglycaemia and hyperglycaemia between users of insulin pump therapy versus multiple daily insulin injections.

Dr Alamoudi of Imam Abdulrahman Bin Faisal National Guard Hospital, Dammam, Saudi Arabia, and others, looked at the differences in glucose control, glucose variability, and rates of hypo- and hyper-glycaemia between the two treatment groups.

Eureka remarks, “Hypoglycaemia is common among patients with type 1 diabetes who fast during Ramadan and is the main cause of having to break the fast.”

Professor Satish Garg of the University of Colorado Denver said, “"In the future, use of an 'artificial pancreas' hybrid closed-loop system during Ramadan may allow patients to reduce or even eliminate hypoglycaemia with increased time-in-range and reduced glucose variability,"